During development, Alzheimer’s blood tests are evaluated against cerebrospinal fluid tests and amyloid PET scans. As of 2026, there are some guidelines that suggest certain highly accurate blood tests could be used instead of a cerebrospinal fluid or an amyloid PET scan to confirm that someone’s cognitive symptoms are caused by Alzheimer’s. Only two of these tests are cleared by the FDA, one for helping confirm an Alzheimer’s diagnosis in a specialist’s office and another to help rule out Alzheimer’s in primary care.